Actavis, Adamas win FDA approval for Alzheimer's drug

(Reuters) - The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc. The drug, Namzaric, is designed to treat moderate-to-severe dementia in Alzheimer's patients who are stabilized with other drugs. Namzaric combines two ingredients in drugs often prescribed together for Alzheimer's in a single capsule. (Reporting by Natalie Grover in Bengaluru; Editing by Joyjeet Das)



via Health News Headlines - Yahoo News http://ift.tt/13ElqIU